Study: Chances of serious side effects from coronavirus vaccines
pubmed.ncbi.nlm.nih.gov
pubmed.ncbi.nlm.nih.gov
The placebo groups for the pfizer cohort and moderna cohort differed in baseline rate by the same magnitude (~25/10000) as the observed effect.
At best, that’s really noisy data.
> At best, that’s really noisy data.
Yes. That's exactly why each of the confidence intervals have a negative and a positive extreme. If there is a real effect, it's below the noise level.
The RR CI must be >= 0. The calculation is based on the incidence in a population and the incidence in a sub-population, which are themselves fractions of positive integers (e.g., 1/1000 and 1/100). I don't think RR can ever be negative, or at least I'm not sure how you would get that without messing up your data or calculations?
RR of >1 means there is excess risk, and <1 means anti-excess risk which is a word I cannot think of right now (just, less risk than the baseline anyway). But RR is also just a measure of risk over baseline to begin with, so a 1.5 RR on something that happens 1/10,000 times is ... not that concerning? I wouldn't be concerned, anyway. Depending on what the risk is, I guess.
So, no, I don't think we would expect RR CI to be centered around zero at all.
The fact that the main effect is so small and crosses from neg to pos is by far more concerning. I would not submit results like that for publication.
Sanity checking results shouldn't be so difficult.
Note, however, that almost all the effects blamed on the vaccine are also effects we see with the virus. Does this not strongly suggest that what we are actually seeing is how the body reacts to the spike protein? If so, that means that if the patients got the real thing they would have the same or worse outcome?
Realistically, the comparison shouldn't be vaccine vs nothing, but vaccine vs infection--and by that yardstick they aren't even in the same ballpark.
Moreover, if there is no effect you expect that some of the intervals are almost centered but you also expect that many of them are very biased. Moreover^2, if there is no effect, You even expect that in a 5% of them the 95% confidence interval does not include 0.
This is a nice trick to detect fake data in blab reports from students. The intervals are too centered.
This is the conclusion by the authors of the paper.
This is the reality of measuring rare events among moderately large groups of people. It’s also possible that any number of unexpected cofounders could have occurred for a small group of people receiving the placebo doses in one segment, such as a small number of placebo doses having an unexpected issue. Impossible to say, which is why large numbers of people are necessary in trials exploring relatively rare events like this.
Regardless, there doesn’t appear to be cause for concern among any of their observed serious events during the study period.
For those about to downvote me: my general (but unscientific) opinion is that it doesn't make sense for the covid vaccine to be riskier than covid itself. But as a society we have shown that even "technical" people like researchers and scientists are willing to fudge, ignore, or misinterpret data for various political or personal purposes, not to mention that doing so in domains outside of public health is common practice in academia. So I believe it's only prudent and rational to be extremely skeptical of anything that looks "off".
https://dailysceptic.org/2022/05/23/concerns-of-fraud-in-pfi...
Another similar problem in which a trial participant appears to have died a day or two after taking the shot, but it was ruled unrelated (by Pfizer!):
https://igorchudov.substack.com/p/pfizer-study-subject-c4591...
Small samples? The confidence intervals look pretty wide.
As I understand it, these are results from two different trials done separately by Pfizer and Moderna, with slightly different protocols and reporting standards:
"Moderna reported SAEs [serious adverse effects] from dose 1 whereas Pfizer limited reporting from dose 1 to 1 month after dose 2."
"For reasons that are not documented in the trial protocol, Moderna included efficacy outcomes in its SAE tabulations, while Pfizer excluded them. As a result, Moderna’s SAE table did not present a traditional SAE analysis but rather an all-cause SAE analysis. "
Thus, only numerical comparisons between treatment and control within the same trial are valid (assuming proper randomization), not between the two trials.
Pfizer reported serious adverse effects in 127 vaccine and 93 placebo. Moderna reported serious adverse effects in 206 vaccine and 195 placebo.
=> Headline: "Serious adverse events of special interest following placebo vaccination in randomized trials in adults"
---
3.4. Harm-benefit considerations
In the Moderna trial, the excess risk of serious AESIs (15.1 per 10,000 participants) was higher than the risk reduction for COVID-19 hospitalization relative to the placebo group (6.4 per 10,000 participants).
In the Pfizer trial, the excess risk of serious AESIs (10.1 per 10,000) was higher than the risk reduction for COVID-19 hospitalization relative to the placebo group (2.3 per 10,000 participants).
---
[1] - https://www.sciencedirect.com/science/article/pii/S0264410X2...
This is a deceptive statistic.
They're only reporting adverse events due to COVID-19 hospitalization in the window of the study.
This will miss adverse events due to undiagnosed COVID-19 and it should be using the participants who contracted COVID-19 as a denominator, since essentially everyone will be infected by the virus eventually and the lifetime-horizon risk in the placebo group is much longer than the window of the study, while the vaccination risk obviously starts with the introduction of the antigen and then drops off rapidly after 3-6 months.
To make it more accurate the placebo groups should have been followed longitudinally for 5-10 years until nearly everyone had seroconverted or tested positive, and compare that against the vaccine group, and compare all outcomes and not apply the diagnosed COVID-19 hospitalization filter to only one arm.
Really bad "study" that is just some bad undergrad-level number crunching and misapplication of statistics to the vaccine trial numbers.
I fully agree that there are plentiful problems with this. Such a study would conclude that smoking cigarettes is perfectly healthy! But going beyond that is generally not possible in any meaningful way, because one cannot see into the future. For instance you now claim, with hindsight, that effectively 100% of people will be infected by COVID. Yet at the same time these studies were happening, we were carrying out actions, ostensibly well informed and in good faith, that promised to be able to effectively eliminate COVID if we just e.g. shut down the country for 'x' weeks.
And so you now want to compare risk(COVID) vs risk(vaccine), but these vaccines ultimately proved themselves unable to meaningfully prevent COVID infection or spread. So instead you need to compare risk(COVID) vs risk(COVID + vaccine). And similarly the vaccines also ended up with brief periods of efficacy, so again you need to factor in yet another variable: risk(COVID + vaccine + boosters x time).
And that's really just getting started. Imagine trying to factor in completely unknowable, yet inevitable, viral mutations. Ultimately, these long term models are more likely to reflect the biases of the person building them than any actual relationship to expected outcomes. And when there are tens of billions of dollars at stake for a model to give the "right" answer, I don't think this is anything we ought ever aim for. Like in software, KISS. [1]
I don't think that's true. Pretty much within a month or two, most of the conversation was around "flatten the curve", which is explicitly not about stopping the total number of cases, but rather lowering the peaks of simultaneous cases.
And when the vaccines came out, it was clear fairly quickly (though maybe after this study? I don't know) that the major benefit of them would be to the severity of the illness, not to prevention of spread.
Insinuating that this study answers that question is just pure bullshit.
On the other hand, the viable ability to set up an insurmountable standard of proof does not really change the picture here. The data available, under the time frames studied, do not paint a positive picture of the safety or efficacy of these drugs. If you get into section 5 of the study, you can see how both the FDA and the pharmaceutical companies worked to pad the numbers to make them look better, including things like lumping thousands of individuals into the experimental group even though there had been no follow up on these individuals, meaning they had no idea of their outcomes.
Geez, you’re raging against the authors for not seeing into the future? The virus has only been here for less than 3 years This is worse than the job requirements that demand 20 years experience in node.js
This study doesn't do that, it can't do that, so it can't answer that question, so it really isn't worth posting that little nugget.
Those are the requirements for answering that question. The study cannot meet those requirements. The study cannot answer that question. Dunno why this math is so difficult.
Personally, I only followed the data for my own band, which was generally stratified as “Male 18 - 40.” I did not see any data that convinced me to begin a course of mRNA injections.
I still caught coronavirus about 2 months later.
> The excess risk of serious adverse events found in our study points to the need for formal harm-benefit analyses
At no point in the pandemic was a harm-benefit analyses even considered for any intervention, action, anything.
It seems plausible that both vaccines cause slightly more serious side effects than their corresponding placebos (30–60% more if I understand correctly), but it's hard to know how meaningful this result is when one of the placebos is 2.5x more 'dangerous' than the other placebo.
Given the small differences and wide confidence intervals, the correct interpretation is that the incidence of side effects isn’t really significantly different than placebo.
Or you could look at the numbers and decide that given the noise of the data that a massively larger study (10-100X more people) would be necessary to discover any practical differences, should they exist.
"The Pfizer trial exhibited a 36 % higher risk of serious adverse events in the vaccine group; risk difference 18.0 per 10,000 vaccinated (95 % CI 1.2 to 34.9); risk ratio 1.36 (95 % CI 1.02 to 1.83). The Moderna trial exhibited a 6 % higher risk of serious adverse events in the vaccine group: risk difference 7.1 per 10,000 (95 % CI -23.2 to 37.4); risk ratio 1.06 (95 % CI 0.84 to 1.33)."
This seems to contradict the first sentence, which implies Moderna is worse:
"Pfizer and Moderna mRNA COVID-19 vaccines were associated with an excess risk of serious adverse events of special interest of 10.1 and 15.1 per 10,000 vaccinated over placebo baselines of 17.6 and 42.2 (95 % CI -0.4 to 20.6 and -3.6 to 33.8), respectively."
I'm not sure how to reconcile the apparent contradiction, perhaps others understand what's being said?
The placebo isn’t relevant, just the fact they didn’t take the vaccine. Since it’s randomized, it’s unsurprising that both groups of unvaccinated people had diff risk outcomes. What IS surprising is that the vaccine performed worse than both random groups of unvaccinated people.
I get that, but why is the quantitative description of the risk different in the first sentence than it is later in the paragraph? The first sentence clearly indicates that the risk is higher with Moderna (excess risk of 15.1 vs 10.1 per 10,000), while later the excess risk of Pfizer is stated as 18.0 per 10,000, while Moderna's is a much lower 7.1 per 10,000. I assume the numbers describe different things, but it isn't clear what the difference is.
Really, if you believe the primary difference is that pfizer was a lower dose and that this isn't all just noise, the data seems to be showing that there's a pretty short window where the risk of the jab wasn't made up for by benefit such that a longer study lost ground on finding a measurable risk.
I am not a statistician, but isn't this saying that there's not enough data to reject the null hypothesis (that the risk difference is 0 and the risk ratio is 1.0) with 95% confidence?
Given that, I won't regret my vaccinations just yet.
So we may someday discover that vaccine misinformation causes people to experience imaginary negative effects from vaccines or placebo.
Most of the adverse effects have frequencies of 1-3, which is literally the lower limit of what kind of data we can use to estimate anything about anything (ask an actuary about modeling "rare events" or "extreme events"). Moreover, what is not reported is the number of affected individuals; there is no indication about whether or not the two poor souls who ended up with pancreatitis in the Moderna trial were also the two people who ended up with diarrhea in the same trial. I am very leery of looking at the sum of these effects and concluding that, in aggregate, the Moderna vaccine is more dangerous than Covid-19 infection (let alone more dangerous than the placebo) when it comes to these "rare" adverse events -- because it doesn't make a lot of sense to aggregate these numbers.
What stands out among all this rare-events noise is the risk of cardiac injury and coagulation disorder. There might actually be some meat on that bone. In the Pfizer trial, we have 8.5 instances of coagulation disorder per 10k versus 5.3 instances per 10k in the placebo. That's not nothing, and might even be "statistically significant" depending on your decision criteria. But again, without a comparison to Covid itself on this particular metric (the "risk reduction" numbers are buried in the text and not clearly enumerated), there's not much you can conclude here.
Feel free to check my work (in R):
coag_vax <- 16
p_vax <- 8.5 / 10000
num_vax <- round(coag_vax / p_vax)
cat("#(vaccine) = ", num_vax, "\n", sep = "")
cat("#(coagulation disorder | vaccine) = ", coag_vax, "\n", sep = "")
cat("P(coagulation disorder | vaccine) = ", p_vax, "\n", sep = "")
cat("\n")
coag_plac <- 10
p_plac <- 5.3 / 10000
num_plac <- round(coag_plac / p_plac)
cat("#(placebo) = ", num_plac, "\n", sep = "")
cat("#(coagulation disorder | placebo) = ", coag_plac, "\n", sep = "")
cat("P(coagulation disorder | placebo) = ", p_plac, "\n", sep = "")
cat("\n")
coag_same <- coag_vax + coag_plac
num_same <- num_vax + num_plac
p_same <- coag_same / num_same
cat("#(null) = ", num_same, "\n", sep = "")
cat("#(coagulation disorder | null) = ", coag_same, "\n", sep = "")
cat("P(coagulation disorder | null) = ", p_same, "\n", sep = "")
cat("\n")
## Frequentist likelihood ratio test that the proportions are identical
# https://stats.stackexchange.com/a/373448/36229
# http://people.musc.edu/~bandyopd/bmtry711.11/lecture_02.pdf
l_same <- dbinom(coag_vax, num_vax, p_same) * dbinom(coag_plac, num_plac, p_same)
l_diff <- dbinom(coag_vax, num_vax, p_vax) * dbinom(coag_plac, num_plac, p_plac)
t <- -2.0 * log(l_same / l_diff)
p <- 1 - pchisq(t, 1)
cat("LR test statistic = ", t, "\n", sep = "")
cat("LR test p-value = ", p, "\n", sep = "")
Output: #(vaccine) = 18824
#(coagulation disorder | vaccine) = 16
P(coagulation disorder | vaccine) = 0.00085
#(placebo) = 18868
#(coagulation disorder | placebo) = 10
P(coagulation disorder | placebo) = 0.00053
#(null) = 37692
#(coagulation disorder | null) = 26
P(coagulation disorder | null) = 0.0006898015
LR test statistic = 1.412184
LR test p-value = 0.2346942
And for a 95% CI around the difference in proportions, I got [0, 8.5]: # https://pubmed.ncbi.nlm.nih.gov/25163425/
# var_vax <- num_vax * p_vax * (1 - p_vax)
# var_plac <- num_plac * p_plac * (1 - p_plac)
var_pooled <- (p_vax * (1 - p_vax) / num_vax) + (p_plac * (1 - p_plac) / num_plac)
std_pooled <- sqrt(var_pooled)
ci_lo <- (p_vax - p_plac) - qnorm(0.975) * std_pooled
ci_hi <- (p_vax - p_plac) + qnorm(0.975) * std_pooled
cat("95% CI (Gaussian approximation) = [ ", max(ci_lo, 0.0) * 10000, " in 10k , ", min(ci_hi, 1.0) * 10000, " in 10k ]\n", sep = "")
Output: 95% CI (Gaussian approximation) = [ 0 in 10k , 8.502481 in 10k ]
I also ran it through a completely-un-tuned Bayesian model and got a similarly inconclusive result: library(brms)
coag_data <- data.frame(
category = c("vaccine", "placebo"),
n_sample = c(num_vax, num_plac),
n_coag = c(coag_vax, coag_plac))
fmla <- n_coag | trials(n_sample) ~ category
prior <- get_prior(fmla, coag_data, family = binomial)
cat("Prior:\n")
print(prior)
model <- brm(
fmla,
data = coag_data,
family = binomial(link = "logit"),
prior = prior,
iter = 1000)
cat("Model:\n")
print(model)
Output (truncated): Population-Level Effects:
Estimate Est.Error l-95% CI u-95% CI Rhat Bulk_ESS Tail_ESS
Intercept -7.58 0.32 -8.23 -6.98 1.00 1000 1278
categoryvaccine 0.49 0.41 -0.27 1.32 1.00 1319 1239
Draws were sampled using sampling(NUTS). For each parameter, Bulk_ESS
and Tail_ESS are effective sample size measures, and Rhat is the potential
scale reduction factor on split chains (at convergence, Rhat = 1).
Conclusion: It's suggestive that the vaccine is more dangerous than the placebo but not at all a strong confirmation.I did skim back over the paper and it looks like they categorized "serious" in such a way that maybe hospitalization is not a terrible baseline for comparison. But it's still pretty questionable that the incidence of "serious" coagulation disorders in the placebo group is higher than the incidence of hospitalization in the placebo group, and it makes me think that they're making an invalid comparison there. So this is an inconclusive result, presented in what is at best a hand-wavey framework.
Hence the general pattern that Moderna hits you harder than Pfizer and of course the hesitant go with Pfizer if given a choice. The flip side is those of us who don't react badly will tend to go Moderna for the boosters. That also means that going forward we can't compare real world effects because the distribution will be decidedly non-random.
Edit: My memory failed me, the spacing was 3 weeks and 4 weeks (Pfizer and Moderna respectively). Point still stands though.
Ref: https://www.medpagetoday.com/opinion/marty-makary/94315
1. The confidence intervals for the risk differences are wide, and some categories include negative numbers. This means that perhaps the vaccines were protective (?) against these other outcomes, but overall the trend based on this analysis is the vaccines were associated with increased risk of these other bad outcomes.
2. Capturing and reporting SAEs in the study designs are sensitive but not specific (i.e. they try to capture everything and aren't particularly concerned with verifying the cause of the SAE). For example, in the Pfizer study, they captured data related to any SAE from the start of consent to 6 months after the last dose of trial vaccine [1]. That is a long time for typical medical problems to crop up. I would like to know a comparison between the intervention group and the estimated rates of such illnesses for an age-matched population.
3. In this study they looked at all SAEs as compared to any SAE (which is what the FDA did). I don't want to discredit they study in any way and it is a valid analysis. However, it is important to keep in mind that when someone becomes ill, injury to one organ system can cause downstream injury to a second (for example a heart attack reduces cardiac output, which causes kidney injury). One way to explain the findings here is that the vaccine triggered more secondary, unintended, bad outcomes. Another way to explain the data is that a small number of people became very ill in the peri-vaccination period and had a lot of bad stuff happen. Also keep in mind from point 2 that the time period for collecting SAEs was from consent to 6 months after the last dose of vaccine.
The data presented here is interesting, and it's possible that the vaccines could be more harmful than initially thought. Overall, I am skeptical. The numbers here are still very low compared to the total number of people in the trial. If patient level data is released and there is more meat to the findings here it might change how I think about vaccination, but at this point I wouldn't change.
[1] https://www.nejm.org/doi/suppl/10.1056/NEJMoa2034577/suppl_f...
1. Were the doses too high? or ...
2. It is something about what was being vaccinating against, or ...
3. the mRNA technology
mRNA vaccine technology seems to be really exciting; what might be done to make them safer? or is there really not special risk to that technology at all?
Medical professionals are recommended to perform a technique called intramuscular aspiration. It helps ensure the vaccine is delivered to a localized area. The technique involves injecting the needle, sucking back on the syringe slightly and looking for blood. If there is no blood, push the contents of the syringe into the muscle and complete the vaccine administration.
If during aspiration there IS blood, it means the needle may have hit a vein or artery in or near the muscle. At that point, administration should be stopped and the medical professional should re-administer the vaccine in a different location.
Here is the theory: Intramuscular aspiration has not been consistently practiced. A certain percentage of covid-19 vaccinations have not been administered locally, but into the circulatory system via a vein or artery. This is not how the vaccine was designed to be administered, and it's not fully clear on what (if any) negative affects may result.
1. This is possible. No real information is public on how dose ranging was done. The closest I could get is the suggestion that doses were calculated based on animal experiments by simply starting high and reducing it until the animals didn't seem to get sick or die anymore. So, doses appear to be the highest tolerable in whatever sample size they used to do this. If there's deeper theory behind the doses it's unclear what it can be because Moderna dosage is 3x stronger than Pfizer for no obvious reason (they are advertised as granting equivalent protection).
2. Yes, vaccinating against CoVs is ~useless and can backfire. There was evidence in the research literature about this before COVID. There are two related problems:
2a. Useless: respiratory viruses like CoVs and influenza can mutate very fast. Nobody ever made a vaccine against the common cold because the viruses mutate beyond it immediately, rendering the vaccine useless. Flu vaccines routinely have efficacy of <20% or even zero because they get made for a variant that doesn't then emerge. It was not a huge leap to realize that the fast mutation problem was also going to apply here, and indeed just months after vaccination started Omicron appeared and replaced Delta completely.
2b. Can backfire: There can be a problem called OAS or antigenic fixation. The immune system appears to lack fine grained resolution. After the immune system memorizes a virus it's possible for it to get confused and think it's detected that virus when in reality it's seeing a slight mutation. When this happens it produces antibodies to the older antigens, and if the virus mutated in such a way that they're now less effective this can lead to the virus not being stopped properly. In other words it can make things worse. Not all viruses are as unstable as CoVs so this problem doesn't occur with e.g. smallpox, but SARS-CoV-2 is very unstable. There's some evidence that COVID vaccines can cause this effect unfortunately, whereby the immune system produces antibodies to the long extinct Wuhan 2019 strain instead of the one the body was actually exposed to.
3. mRNA tech is very neat in theory but there are two major possible issues:
3a. It never launched before COVID because it was plagued with extremely severe toxicity problems that caused any drug using it to fail trials / safety approvals. The problem seemed to be the lipid nanoparticle wrapper which became toxic on repeat doses. Most drugs require repeat doses so that's a problem. Moderna was a failing biotech firm before COVID because of this. They couldn't find a solution so pivoted to vaccines. Why? Because - pre COVID - vaccines were assumed to be something you take once and then you're done for many years or for life, so it was a way to dodge the repeat-dose-toxicity problem rather than solve it. Well, then COVID mass hysteria infected the globe and people are being forced to take 2, 3, 4 doses. So we're well into repeat doses territory. How many doses did Moderna's tech become toxic after, exactly? That's not public AFAIK.
https://www.statnews.com/2017/01/10/moderna-trouble-mrna/
3b. We were assured that the mRNA disappears from the body within a few days. That turned out to be false and mRNA spike can be found collecting in different parts of the body weeks or even months after injection. Because research that could undermine vaccines is so rare and hard to get published, and because mRNA vaccines are so new, why this happens is unclear. However some doctors have speculated that it's to do with the pseudo-uridine substitutions they do. (mRNA vaccines disable the immune system's normal defenses against foreign mRNA using some chemical tricks).
On the other hand, mRNA itself is probably not the cause of the heart/clotting problems. AstraZeneca's vaccine doesn't use mRNA and has the same issues. The problem is more likely that the spike protein is toxic and can cause these problems if it gets into the bloodstream. Doesn't matter how you make it.
In this case, the problem is that it accelerates the spread. Normally in any epidemic there's a large population of people who were never infected, so it's their first time and the body becomes highly immune. They act as buffers that stop the virus from spreading so fast to those unlucky enough to have got the earlier version. You end up with a diverse population of people immune to different variants which slows them all down.
If you fix everyone on a variant that hasn't existed for years then this buffering effect is eliminated. Everyone becomes equally vulnerable to reinfection. This is posited as the explanation for why do many vaccinated people seem to be susceptible to rapid reinfection. Although it can be happen naturally too, the wider social diversity that would make that happen say every few years is gone, so now it can happen every few months instead.
Some vaccines used a lipid shell to get around the problems of raw MRNA being really fragile. However, it seems they made the protection too good, and MRNA that was supposed to just stay in the arm easily travelled further and got into the bloodstream. That means that MRNA was getting into cells all around the body and causing spike protein production everywhere, instead of just in the arm like designed.
This means that you got inflammation problems everywhere in the body, including in the heart (myocarditis/pericarditis), vascular systems ("brain fog", general unwellness), and reproductive systems (especially for women).
Inflammation in the injection site for a vaccine is pretty normal, inflammation elsewhere is terrible.
Initial optimistic assumptions of the MRNA being permanently consumed by the body relatively quickly also don't seem to be true - even the CDC recently edited a page on MRNA vaxxes to remove a statement that the MRNA is used up quickly. The very worst case scenario could be people who got vaxxed just have cells pumping out inflammatory spike protein at a low rate for years.
Other vaccines used a real virus vector that is modified version to express spike protein. This of course has the issue of a virus being not entirely controllable once it's in the body. Again, you'll have the problem of the virus (and thus the spike protein it expresses) ending up in strange places. However, the immune profile is slightly different, as the immune system will start to attack the vaccine vector as it progresses in the body.
Several vaccines were associated with strange, systemic blood clotting in some people - but I'm not sure if they ever found the mechanism of action.
Novavax uses a traditional protein+adjuvant mix seen in many previous vaxxes. There's no widespread report of nasty side effects with Novavax - but there's not that much usage of Novavax in the wild either.
Aside from that, there's also the issue that in targeting a variant of the rapidly-mutating spike protein, you set people up to be victim to the long-known "original antigenic sin" effect.
Immune system works off a principle of first impression - it targets a response to whatever it sees first. This also applies to infections that are somewhat close but not the same as what is 'memorised' by the immune system already. So an infection by a COVID variant when the person has been exposed to a vaccine for the originals will produce an immune response for the modified original protein, not the real infection that is currently happening. (The vaccines target a modified original spike protein, and not the S-shape protein as well, so the distance is even greater.) Since the spike protein keeps shifting so fast in the wild, hitting the OAS effect is really likely over time.
Some people think the S-protein in the middle of COVID should have been targeted by the vaccines, not the spikes, as it's more stable. It's hard to know if that would have been more effective.
We really need cost-benefits of adverse effects v. COVID outcomes stratified by ages, and it takes more than one study to build the picture.
Also when taking this into account, one must take note that many who have had the vaccine still end up getting COVID at some point, so the additional adverse effects that COVID brings may add onto any risks the vaccine brought.
[1] - https://www.sciencedirect.com/science/article/pii/S0264410X2...
This feels like we’re looking at some sort of subset rather than overall risk profile?
Don’t think anyone was expecting vaccines to be entirely risk free.